Global BCL B Cell Lymphoma Inhibitors Market Size | COVID-19 Impact Analysis | Forecast to 2027
The global BCL B cell lymphoma inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). BCL-2, also known as B Cell Lymphoma 2, is a protein-encoding gene belonging to the B cell lymphoma family. The market growth is majorly attributable to the growth in the prevalence of diffuse B cell lymphoma, a common type of non-Hodgkin lymphoma. For instance, according to an article by Lymphoma Research Foundation in 2019, in the US, DLBCL accounted for 22% of newly diagnosed B cell lymphoma cases. Around 18,000 people globally are diagnosed with DLBCL each year.
Adding to this, the disease
affects people over 60 years of age. According to the American Cancer Society
in 2019, an estimated 20,720 people were diagnosed with chronic lymphocytic lymphoma.
Moreover, 90% of the people diagnosed with this form of lymphoma are estimated
to affect people above 50 years of age. In the US, 2,220 men and 1,710 women
are expected to be suffering from chronic lymphocytic lymphoma every year.
Moreover, as per the American Cancer Society, about 3,930 mortalities were
anticipated to take place in 2019.
To Request a Sample of our Report on Global BCL B Cell
Lymphoma Inhibitors Market: https://www.omrglobal.com/request-sample/bcl-b-cell-lymphoma-inhibitors-market
Further, there are various inhibitor drugs being approved in the market
that spur market growth. For instance, Venetoclax is the only and first
approved FDA BCL-2 inhibitor drug for chronic lymphocytic lymphoma patients.
Although various clinical trials are being carried out for the development of
new BCL-2 inhibitors.
Some key players operating in the market include AbbVie, Roche, Abcam,
Biorbyt, Biovison, and Tocris Bioscience. These players are eyeing on
strengthening their position in the market by adopting various strategies as
mergers and acquisitions, partnerships, collaborations, new product launch and
development in the existing product portfolio, and so on.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
·
Segment Covered
·
Regions Covered- Globally
·
Competitive Landscape: AbbVie, Roche,
Abcam, Biorbyt, Biovison, and Tocris Bioscience
(Get 15% Discount on Buying this Report)
A
full Report of Global BCL B Cell Lymphoma Inhibitors Market is Available
at: https://www.omrglobal.com/industry-reports/bcl-b-cell-lymphoma-inhibitors-market
Global BCL B Cell Lymphoma Inhibitors Market - Segmentation
By Therapy
• Monotherapy
• Combination Therapy
By Type
• Positive Lymphoma
• Follicular Lymphoma
Global BCL B Cell Lymphoma Inhibitors Market Segmentation by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment